Madrigal Pharmaceuticals, Inc. (MDGL)
499.40
-0.31
(-0.06%)
USD |
NASDAQ |
Oct 02, 16:00
499.58
+0.18
(+0.04%)
Pre-Market: 20:00
Madrigal Pharmaceuticals Net Income (Quarterly) : -57.94M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -57.94M |
| March 31, 2026 | -94.39M |
| December 31, 2025 | -58.58M |
| September 30, 2025 | -114.19M |
| June 30, 2025 | -42.28M |
| March 31, 2025 | -73.24M |
| December 31, 2024 | -59.42M |
| September 30, 2024 | -106.96M |
| June 30, 2024 | -151.97M |
| March 31, 2024 | -147.54M |
| December 31, 2023 | -112.19M |
| September 30, 2023 | -98.74M |
| June 30, 2023 | -85.80M |
| March 31, 2023 | -76.90M |
| December 31, 2022 | -85.90M |
| September 30, 2022 | -81.20M |
| June 30, 2022 | -70.73M |
| March 31, 2022 | -57.52M |
| December 31, 2021 | -64.55M |
| September 30, 2021 | -63.10M |
| June 30, 2021 | -61.65M |
| March 31, 2021 | -52.55M |
| December 31, 2020 | -59.12M |
| September 30, 2020 | -57.96M |
| June 30, 2020 | -49.02M |
| Date | Value |
|---|---|
| March 31, 2020 | -36.14M |
| December 31, 2019 | -27.74M |
| September 30, 2019 | -21.43M |
| June 30, 2019 | -19.70M |
| March 31, 2019 | -15.08M |
| December 31, 2018 | -11.48M |
| September 30, 2018 | -8.512M |
| June 30, 2018 | -6.46M |
| March 31, 2018 | -6.364M |
| December 31, 2017 | -8.445M |
| September 30, 2017 | -8.363M |
| June 30, 2017 | -8.347M |
| March 31, 2017 | -5.999M |
| December 31, 2016 | -7.749M |
| September 30, 2016 | -14.05M |
| June 30, 2016 | -2.877M |
| March 31, 2016 | -1.713M |
| December 31, 2015 | -1.883M |
| September 30, 2015 | -1.800M |
| June 30, 2015 | -19.80M |
| March 31, 2015 | -20.71M |
| December 31, 2014 | -20.35M |
| September 30, 2014 | -19.97M |
| June 30, 2014 | -22.29M |
| March 31, 2014 | -23.56M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Exelixis, Inc. | 212.05M |
| Insmed, Inc. | -13.24M |
| United Therapeutics Corp. | 333.00M |
| Karyopharm Therapeutics, Inc. | -67.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 364.25M |
| Total Expenses (Quarterly) | 422.19M |
| EPS Diluted (Quarterly) | -1.988 |
| Enterprise Value | 11.04B |
| Gross Profit Margin (Quarterly) | 88.91% |
| Profit Margin (Quarterly) | -15.91% |
| Earnings Yield | -2.58% |
| Normalized Earnings Yield | -2.563 |